PROTHENA CORP PLC (PRTA) Stock Overview
NASDAQ:PRTA - IE00B91XRN20 - Common Stock
PRTA Key Statistics, Chart & Performance
The current stock price of PRTA is 8.77 USD. In the past month the price increased by 31.29%. In the past year, price decreased by -59.6%.
PRTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About PRTA
Company Profile
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Company Info
PROTHENA CORP PLC
77 Sir John Rogersons Quay, Block C, Grand Canal Docklands
DUBLIN D02 VK60 IE
CEO: Gene G. Kinney
Employees: 163
Phone: 35312362500
PROTHENA CORP PLC / PRTA FAQ
What is the stock price of PROTHENA CORP PLC today?
The current stock price of PRTA is 8.77 USD. The price increased by 2.45% in the last trading session.
What is the ticker symbol for PROTHENA CORP PLC stock?
The exchange symbol of PROTHENA CORP PLC is PRTA and it is listed on the Nasdaq exchange.
On which exchange is PRTA stock listed?
PRTA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROTHENA CORP PLC stock?
14 analysts have analysed PRTA and the average price target is 26.52 USD. This implies a price increase of 202.39% is expected in the next year compared to the current price of 8.77. Check the PROTHENA CORP PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROTHENA CORP PLC worth?
PROTHENA CORP PLC (PRTA) has a market capitalization of 472.09M USD. This makes PRTA a Small Cap stock.
How many employees does PROTHENA CORP PLC have?
PROTHENA CORP PLC (PRTA) currently has 163 employees.
What are the support and resistance levels for PROTHENA CORP PLC (PRTA) stock?
PROTHENA CORP PLC (PRTA) has a support level at 8.76 and a resistance level at 12.86. Check the full technical report for a detailed analysis of PRTA support and resistance levels.
Is PROTHENA CORP PLC (PRTA) expected to grow?
The Revenue of PROTHENA CORP PLC (PRTA) is expected to decline by -81.97% in the next year. Check the estimates tab for more information on the PRTA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROTHENA CORP PLC (PRTA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRTA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRTA, evaluating the profitability, health, valuation and growth aspects
- PROTHENA CORP PLC (PRTA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROTHENA CORP PLC (PRTA) Sales and EPS estimates to see what analysts future expectations are.
- PROTHENA CORP PLC (PRTA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROTHENA CORP PLC (PRTA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROTHENA CORP PLC (PRTA) Stock Chart to make your own analysis
- PROTHENA CORP PLC (PRTA) Latest news and press-releases to stay up to date.
Does PROTHENA CORP PLC (PRTA) stock pay dividends?
PRTA does not pay a dividend.
When does PROTHENA CORP PLC (PRTA) report earnings?
PROTHENA CORP PLC (PRTA) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of PROTHENA CORP PLC (PRTA)?
PROTHENA CORP PLC (PRTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.03).
What is the Short Interest ratio of PROTHENA CORP PLC (PRTA) stock?
The outstanding short interest for PROTHENA CORP PLC (PRTA) is 10.12% of its float. Check the ownership tab for more information on the PRTA short interest.
PRTA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PRTA. When comparing the yearly performance of all stocks, PRTA is a bad performer in the overall market: 86.53% of all stocks are doing better.
PRTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRTA. While PRTA has a great health rating, there are worries on its profitability.
PRTA Financial Highlights
Over the last trailing twelve months PRTA reported a non-GAAP Earnings per Share(EPS) of -5.03. The EPS decreased by -403% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.91% | ||
| ROE | -93.4% | ||
| Debt/Equity | 0 |
PRTA Forecast & Estimates
14 analysts have analysed PRTA and the average price target is 26.52 USD. This implies a price increase of 202.39% is expected in the next year compared to the current price of 8.77.
For the next year, analysts expect an EPS growth of -78.72% and a revenue growth -81.97% for PRTA